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The peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily. These
receptors are also ligand-dependent transcription factors responsible for the regulation of cellular events that range from glucose
and lipid homeostases to cell diﬀerentiation and apoptosis. The importance of these receptors in lipid homeostasis and energy
balance is well established. In addition to these metabolic and anti-inﬂammatory properties, emerging evidence indicates that
PPARs can function as either tumor suppressors or accelerators, suggesting that these receptors are potential candidates as drug
targets for cancer prevention and treatment. However, conﬂicting results have emerged regarding the role of PPARs on colon
carcinogenesis. Therefore, further investigation is warranted prior to considering modulation of PPARs as an eﬃcacious therapy
for colorectal cancer chemoprevention and treatment.
Copyright © 2008 D. Wang and Raymond N. DuBois. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Understanding the biology of intestinal epithelial cells may
reveal the molecular pathogenesis of a number of digestive
diseases. One such disease, colorectal cancer (CRC), leads to
signiﬁcant cancer-related morbidity and mortality in most
industrialized countries. Initiation and progression of CRC
are a complex process that results fromthe loss of the normal
regulatory pathways that govern a balance between epithelial
cell proliferation and death. For example, alterations in
multiple pathways such as Wnt/APC, COX-2, and Ras are
known to play major roles in CRC progression. The standard
treatment for advanced malignancies has improved greatly
over the past decade but is still not satisfactory. Therefore,
signiﬁcant eﬀort has been exerted to identify novel drug
targets for both the prevention and treatment of this disease.
One group of compounds found to decrease the risk of
colorectal cancer includes nonsteroidal anti-inﬂammatory
drugs (NSAIDs), which target the cyclooxygenase enzymes
(COX-1 and COX-2). However, prolonged use of high doses
of these inhibitors (except for aspirin) is associated with
unacceptablecardiovascularsideeﬀects[1–3].Thus,itisnow
crucial to develop more eﬀective chemopreventive agents
with minimal toxicity and maximum beneﬁt.
Dietary fat intake is an environmental factor that is
associated with some human diseases such as diabetes,
obesity, and dyslipidemias. Some nuclear hormone receptors
play a central role in regulating nutrient metabolism and
energy homeostasis. These nuclear receptors are activated
by natural ligands, including fatty acids and cholesterol
metabolites. Among these receptors, special attention has
beenfocusedonthemembersoftheperoxisomeproliferator-
activated receptors (PPARs) family, which were initially
identiﬁed as mediators of the peroxisome proliferators in
the early 1990s [4]. PPARs play a central role in regulating
the storage and catabolism of dietary fats via complex
metabolic pathways, including fatty acid oxidation and
lipogenesis [5]. To date, three mammalian PPARs have
been identiﬁed and are referred to as PPARα (NR1C1),
PPARδ/β (NR1C2), and PPARγ (NR1C3). Each PPAR iso-
type displays a tissue-selective expression pattern. PPARα
and PPARγ are predominantly present in the liver and
adipose tissue, respectively, while PPARδ expresses in diverse
tissues [6]. In common with other members of the type II2 PPAR Research
steroid hormone receptor superfamily, PPARs are ligand-
dependent transcription factors and form heterodimers
with another obligate nuclear receptors, such as retinoid X
receptors (RXRs) [4, 7, 8]. Each PPAR-RXR heterodimer
binds to the peroxisome proliferator responsive element
(PPRE) located in the promoter region of responsive
genes.
It is well established that modulation of PPAR activity
maintains cellular and whole-body glucose and lipid home-
ostases.Hence,greateﬀortshavebeenmadetodevelopdrugs
targeting these receptors. For example, PPARγ synthetic
agonists, rosiglitazone and pioglitazone, are antidiabetic
agents which suppress insulin resistance in adipose tissue.
The antiatherosclerotic and hypolipidemic agents including
fenoﬁbrate and gemﬁbrozil are PPARα synthetic agonists
that induce hepatic lipid uptake and catabolism. Genetic
and pharmacological studies have also revealed important
roles of PPARδ in regulating lipid metabolism and energy
homeostasis. Genetic studies indicate that overexpression of
constitutively active PPARδ in mouse adipose tissue reduced
hyperlipidemia, steatosis, and obesity induced by either
genetics or a high-fat diet. In contrast, PPARδ null mice
treated in similar fashion exhibited an obese phenotype
[9]. Pharmacologic studies demonstrate that the PPARδ
selective-agonist (GW501516) attenuated weight gain and
insulin resistance in mice fed with high-fat diets [10]
and increased HDL-C while lowering tryglyceride levels
and insulin in obese rhesus monkeys [11]. Furthermore,
preclinical studies revealed that PPARδ agonists diminished
metabolic derangements and obesity through increasing
lipid combustion in skeletal muscle [12]. These results
suggest that PPARδ agonists are potential drugs for use
in the treatment of dyslipidemias, obesity, and insulin
resistance. Therefore, the PPARδ agonist (GW501516) is
currently in phase III clinical trials to evaluate its use for
treatment of patients with hyperlipidemias and obesity.
However, recent studies showing that some agonists of
PPARs promote carcinogenesis in animal models have raised
concerns about using these agonists for the treatment of
metabolic diseases. For example, long-term administration
of a PPARα agonist induces the development of hepato-
carcinomas in mice but not in PPARα null animals, con-
clusively demonstrating that PPARα mediates these eﬀects
in promoting liver cancer [13]. Furthermore, the PPARδ
agonist (GW501516) accelerates intestinal polyp growth
in ApcMin/+ mice [14, 15]. These results raise concerns
for developing this class of agents for human use and
support the rationale for developing PPARδ antagonists as
chemopreventive agents.
2. PPARs AND COLORECTAL CANCER
Signiﬁcant eﬀort has been concentrated on deducing the
role of PPARs in CRC and other cancers. A large body of
evidence indicates that PPARγ serves as a tumor suppressor.
Contradictory evidencessuggestthat PPARδ canactas either
a tumor suppressor or tumor promoter. A few evidences
support a role of PPARα in CRC.
2.1. PPARα
Although the tumor-promoting eﬀects of PPARα in hep-
atocarcinomas are clear, less is known about the role of
PPARα in human tumors. Generally, activation of PPARα by
exogenous agonists causes inhibition of tumor cell growth
in cell lines derived from CRC, melanoma, and glial brain
tumors [16–18]. There is no evidence showing that PPARα
expression is elevated in human cancers.
2.2. PPARγ
The prominent role of PPARγ in regulating cellular diﬀer-
entiation prompted a great eﬀort to investigate the function
of PPARγ in cancer ﬁeld. While PPARγ is elevated in CRC
[19], suggesting that this receptor may contribute to tumor
biology, studies of PPARγ mutation in CRC from humans,
animals, and cultured cells produced controversial results.
One study showed that 8% of primary human colorectal
tumors had a loss of function mutation in one allele of
the PPARγ gene [20]. Recent data revealed that a Pro12Ala
(P12A) polymorphism in the PPARγ gene is associated with
increased risk of CRC [21, 22]. These results suggest a
putative role for this receptor as a tumor suppressor. In
contrast, another study showed that mutant PPARγ gene has
not been detected in human colon tumor samples and CRC
cell lines, suggesting that PPARγ mutations in human CRC is
ar a r ee v e n t[ 23].
In vitro studies show that activation of PPARγ results
in growth arrest of colon carcinoma cells through induc-
tion of cell-cycle arrest or/and apoptosis. Several potential
downstream targets of PPARγ for mediating antitumor
eﬀects of PPARγ have been identiﬁed in various cancer
cell types. Activation of PPARγ negatively regulatescell cycle
progression by modulating a number of cell cycle regulators:
(1) inhibiting E2F activity in transformed adipogenic cells
[24], (2) Rb hyperphosphorylation in vascular smooth
muscle cells and pituitary adenoma cells [25, 26], (3) cyclin
D1 expression in Ras-transformed intestinal epithelial cells,
pancreatic, or breast cancer cells [27–29], and (4) inducing
CDK inhibitor expression such as p18, p21, and p27 in
hepatoma cells [30]. Activation of PPARγ has also been
reported to inhibit tumor cell growth by upregulation of
the transcriptional repressor TSC22 in colon cancer cells
[31] and GADD153 in nonsmall-cell lung carcinoma cells
[32]. PPARγ agonists induce apoptosis by induction of
PTENexpressioninpancreatic,breast,andcoloncancercells
[33] and inhibition of NFκB and Bcl-2 expression in colon
cancer cells [34]. Moreover, PPARγ exhibits antiangiogenic
eﬀects by inhibiting VEGF expression in tumor cells and
VEGF receptors in endothelial cells [35, 36]. It has also
been reported that PPARγ agonists suppress tumor cell
invasion in colon and breast cancer cells by downregulation
of matrix metalloproteinase-7 (MMP-7) and induction of
MMP inhibitors [37, 38]. In addition, the ability of PPARγ
to suppress tumor growth is also through inhibiting APC/β-
catenin and COX-2/PGE2 signaling pathways, which are
pivotally involved in colon carcinogenesis [39–42].D. Wang and Raymond N. DuBois 3
However, the role of PPARγ in colorectal cancer progres-
sion is controversial because there are conﬂicting results in
mouse models of colon cancer. Although PPARγ agonists
inhibit colorectal carcinogenesis in xenograft models and
in the azoxymethane (AOM)-induced colon cancer model
[43, 44], these drugs are reported to have both tumor-
promoting and tumor-inhibiting eﬀects in a mouse model
for familial adenomatous polyposis, the ApcMin/+ mouse. It
has been reported that administration of PPARγ agonists
signiﬁcantly increases the number of colon adenomas in
the ApcMin/+ mice [45–47] and even in wild-type C57BL/6
mice [48]. However, other studies show that treatment of 2
diﬀerent Apc-mutant models (ApcMin/+ and ApcΔ1309)w i t h
the PPARγ agonist pioglitazone resulted in reduction in the
number of both small and large intestinal polyps in a dose-
dependent manner [49, 50]. These paradoxical observations
appear to have been resolved by genetic studies showing
that the heterozygous disruption of PPARγ is suﬃcient
to increase tumor number in AOM-treated mice and that
intestinal-speciﬁc PPARγ knockout promotes tumor growth
in ApcMin/+ mice [39, 51]. These genetic evidences support
the hypothesis that PPARγ serves as tumor suppressor in
colorectal cancer. One possible explanation for the diﬀer-
ences in phenotype caused by pharmaceutical versus genetic
manipulation of PPARγ i nm o u s em o d e l sm a yb ed u et o
the PPARγ-independent eﬀect of the agonist drugs, drug
doses used, and animal models employed. This controversial
extends beyond CRC. For example, data are conﬂicting from
diﬀerent animal models of breast cancer as well. PPARγ
agonist suppresses NMU-induced mammary carcinomas
[52]. However, overexpression of a constitutively active form
ofPPARγ acceleratesmammaryglandtumordevelopmentin
MMTV-PyV transgenic mice [53].
2.3. PPARδ
PPARδ has been shown to play an important role in
embryo implantation [54], atherogenic inﬂammation [55],
regulating cell survival in the kidney following hypertonic
stress [56], and skin following wound injury [57, 58].
The role of PPARδ in colorectal carcinogenesis is more
controversial than that of PPARγ. The ﬁrst evidence linking
the PPARδ to carcinogenesis actually emerged from studies
on gastrointestinal cancer. PPARδ is elevated in most human
colorectal cancers and in tumors arising in the ApcMin/+
mice, and AOM-treated rats [59, 60]. Importantly, the
PPARδ proteins are accumulated only in human CRC cells
with highly malignant morphology [61]. Downregulation
of PPARδ is correlated with antitumor eﬀects of dietary
ﬁsh oil/pectin in rats treated with radiation and AOM [62].
PPARδ was identiﬁed as a direct transcriptional target of
APC/β-catenin/Tcf pathway and as a repression target of
NSAIDs [59, 63]. A case-control study in a large popula-
tion showed that the protective eﬀect of NSAIDs against
colorectal adenomas was reported to be modulated by a
polymorphism in the PPARδ gene [64]. PPARδ expression
and activity are also induced by oncogenic K-ras [65].
In addition, COX-2-derived PGl2 directly transactivates
PPARδ [60], and COX-2-derived PGE2 indirectly induces
PPARδ activation in CRC, hepatocellular carcinoma, and
cholangiocarcinoma cells [66–68]. These studies indicate
that PPARδ is a focal point of cross-talk between these
signaling pathways.
In a murine xenograft cancer model, the disruption of
both PPARδ alleles in human HCT-116 colon carcinoma
cells decreased tumorigenicity, suggesting that activation of
PPARδ promotes tumor growth [69]. However, PPARδ has
been reported to have both tumor-promoting and tumor-
inhibiting eﬀects based on conﬂicting data obtained from
mouse models of colon cancer. For example, activation of
PPARδ by a selective synthetic PPARδ agonist (GW501516)
or a PPARδ endogenous activator (PGE2) accelerates intesti-
nal adenoma growth in ApcMin/+ mice by promoting tumor
cell survival [14,66].Asubsequentgeneticstudyshowedthat
deletion of PPARδ attenuates both small and large intestinal
adenoma growth, and PPARδ is required for the tumor-
promoting eﬀects of PPARδ ligand (GW501516) and PGE2
in ApcMin/+ mice [15, 66]. Another study showed that loss
of PPARδ in ApcMin/+ mice signiﬁcantly reduced growth
of tumors larger than a diameter of 2mm, even though
PPARδ deﬁciency did not aﬀect overall tumor incidence
[70]. In contrast to these reports suggesting that PPARδ
serves as tumor accelerator, recent conﬂicting reports show
that PPARδ deﬁciency enhances polyp growth in ApcMin/+
and AOM-treated mice in the absence of exogenous PPARδ
stimulation [71, 72]. Moreover, a PPARδ ligand (GW0742)
inhibits colon carcinogenesis in AOM-treated mice but
promotes small intestinal polyp growth in ApcMin/+ mice
[73].
One explanation for these disparate results may be due
to diﬀerences in the genetic background of ApcMin/+ mice,
animal breeding, or possibly to diﬀerences in the speciﬁc
targeting strategy employed to delete PPARδ.F o re x a m p l e ,
the average number of polyps in 13-week old ApcMin/+
mice on a C57BL/6 genetic background is about 50, while
the polyp number in ApcMin/+ mice on a mixed-genetic-
background (C57BL/6 × 129/SV) is about 120. Our results
also show that the breeding strategy aﬀects the number and
size of polyps in mice even on the same genetic background.
Mice generated by breeding female PPARδ−/−/ApcMin/+ with
male PPARδ−/−/Apc+/+ exhibit increased adenoma number
with a larger average size than those obtained by breeding
female PPARδ−/−/Apc+/+ with male PPARδ−/−/ApcMin/+.
Finally, the PPARδ null mice we studied were obtained
from Beatrice Desvergne in Switzerland. These mice were
generated by deleting exons 4 and 5 encoding the DNA
binding domain [74] ,w h i l eP e t e r sg r o u pg e n e r a t e dt h e
PPARδ knockout mice by inserting a neomycin resistance
cassette into the last exon (exon 8) [75]. It has been
suggestedthatthestrategyemployedtodisruptPPARδ bythe
Peters group might have led to a hypomorphic allele, which
retainssomeaporeceptorfunction,thusmakingitdiﬃcultto
correctly interpret their results. Indeed, conﬂicting results in
the context of embryonic lethality have also been observed
from these two PPARδ mutant mouse strains [74, 75]. To
further clarify the role of PPARδ in colorectal tumorigenesis,
it is important to investigate the role of PPARδ in animal
models that are dependent on activation of other oncogenes4 PPAR Research
PPARγ PPARδ
PPARγ
PPARδ
Cell death Cell survival Cell death Cell survival
Normal Tumor
Figure 1: A potential model for PPARs regulating colorectal tumor
growth.
or disruption of other tumor suppressors to verify our
conclusions that activation of PPARδ is proneoplastic.
Studies in other types of cancer also support the
hypothesis that PPARδ serves as a tumor accelerator. A
selective PPARδ agonist (GW501516) has been shown
to stimulate proliferation of human breast, prostate, and
hepatocellular carcinoma cells [68, 76, 77]. In a xenograft
model, blocking PPARδ activation reduced ovarian tumor
growth [78]. PPARδ knockout mice exhibited signiﬁcant
impaired angiogenesis and tumor growth after these mice
were injected s.c. with mouse Lewis lung carcinoma and
melanoma cells [79]. In a mouse mammary tumor model,
treatment with the PPARδ agonist (GW501516) accelerated
tumor formation, while a PPARγ agonist (GW7845) delayed
tumor growth [80]. Taken together, the role of PPARδ in
cancer biology remains unclear.
3. SUMMARY
Despite extensive research on both PPARγ and PPARδ in
CRC, the role of these receptors remains highly controversial
inthisdisease.Emergingevidencedemonstratesthatcooper-
ativeinteractionsbetweenWnt,COX-2,andPPARssignaling
pathways can initiate cellular transformation and promote
progression of colorectal cancer. These studies provide
support for evaluating the eﬃcacy of PPARδ antagonists for
cancer prevention and/or treatment. We propose a potential
working model as a useful starting point for future studies
(see Figure 1).
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